Alpha‐Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism

Many neurodegenerative diseases associated with functional Tau dysregulation, including Alzheimer's disease (AD) and other tauopathies, also show α‐synuclein (α‐Syn) pathology, a protein associated with Parkinson's disease (PD) pathology. Here we show that treatment of primary mesencephalic neurons (48 h) or subchronic treatment of wild‐type (WT) mice with the Parkinsonism‐inducing neurotoxin MPP+/MPTP, results in selective dose‐dependent hyperphosphorylation of Tau at Ser396/404 (PHF‐1‐reactive Tau, p‐Tau), with no changes in pSer202 but with nonspecific increases in pSer262 levels. The presence of α‐Syn was absolutely mandatory to observe MPP+/MPTP‐induced increases in p‐Tau levels, since no alterations in p‐Tau were seen in transfected cells not expressing α‐Syn or in α‐Syn‐/‐ mice. MPP+/MPTP also induced a significant accumulation of α‐Syn in both mesencephalic neurons and in WT mice striatum. MPTP/MPP+ lead to differential alterations in p‐Tau and α‐Syn levels in a cytoskeleton‐bound, vs. a soluble, cytoskeleton‐free fraction, inducing their coimmunoprecipitation in the cytoskeleton‐free fraction and neuronal soma. Subchronic MPTP exposure increased sarkosyl‐insoluble p‐Tau in striatum of WT but not α‐Syn‐/‐ mice. These studies describe a novel mechanism for MPTP neurotoxicity, namely a MPTP‐inducible, strictly α‐Syn‐dependent, increased formation of PHF‐1‐reactive Tau, suggesting convergent overlapping pathways in the genesis of clinically divergent diseases such as AD and PD. —Duka, T., Rusnak, M., Drolet, R. E., Duka, V., Wersinger, C., Goudreau, J. L., Sidhu, A. Alpha‐synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. FASEB J. 20, 2302–2312 (2006)

[1]  T. Hastings,et al.  Could a loss of alpha-synuclein function put dopaminergic neurons at risk? , 2004, Journal of neurochemistry.

[2]  M. Goedert,et al.  Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. , 1998, Molecular psychiatry.

[3]  J. Trojanowski,et al.  Lewy body pathology in Alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[4]  M. Palkovits,et al.  Isolated removal of hypothalamic or other brain nuclei of the rat. , 1973, Brain research.

[5]  A. Sidhu,et al.  α‐Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease , 2004 .

[6]  D. D. Di Monte,et al.  Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. , 2005, Neurobiology of disease.

[7]  A. Sidhu,et al.  Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. , 2005, Biochemistry.

[8]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[9]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[10]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[11]  D. Loo,et al.  Measurement of cell death. , 1998, Methods in cell biology.

[12]  S. Mandel,et al.  Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. , 2004, Journal of molecular neuroscience : MN.

[13]  Alexxai V. Kravitz,et al.  Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation , 2004, Experimental Neurology.

[14]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[15]  Taro Saito,et al.  Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. , 2004, Journal of Alzheimer's disease : JAD.

[16]  K. Titani,et al.  Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*) , 1995, The Journal of Biological Chemistry.

[17]  E. Mandelkow,et al.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding , 1993, Neuron.

[18]  A. Sidhu,et al.  Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Taro Saito,et al.  Demonstration of a role for α-synuclein as a functional microtubule-associated protein , 2004 .

[20]  J. Trojanowski,et al.  Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*) , 1995, The Journal of Biological Chemistry.

[21]  Jun Hu,et al.  A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. , 2003, Biochemistry.

[22]  R. Hen,et al.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. , 2001, The EMBO journal.

[23]  I. Grundke‐Iqbal,et al.  Metabolic/signal transduction hypothesis of Alzheimer’s disease and other tauopathies , 2005, Acta Neuropathologica.

[24]  Y. Ihara,et al.  Alzheimer's disease: β‐Amyloid protein and tau , 2002, Journal of neuroscience research.

[25]  T. Hastings,et al.  Could a loss of α‐synuclein function put dopaminergic neurons at risk? , 2004 .

[26]  K. Kosaka,et al.  Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease , 1999, Neuroscience Letters.

[27]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[28]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[29]  Robert E. Schmidt,et al.  The alpha-synuclein mutation E46K promotes aggregation in cultured cells , 2006, Experimental Neurology.

[30]  M. Goedert,et al.  Lewy body diseases and multiple system atrophy as α-synucleinopathies , 1998, Molecular Psychiatry.

[31]  D. Dickson,et al.  Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility , 2002, Journal of neurochemistry.

[32]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[33]  M. Youdim,et al.  Iron and α-synuclein in the substantia nigra of MPTP-treated mice , 2007, Journal of Molecular Neuroscience.

[34]  Khadija Iqbal,et al.  Levels of tau phosphorylation at different sites in Alzheimer disease brain , 1998, Neuroreport.

[35]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[36]  C. Stichel,et al.  The mouse MPTP model: gene expression changes in dopaminergic neurons , 2003, The European journal of neuroscience.

[37]  Philippe Vernier,et al.  Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[39]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[40]  Alexxai V. Kravitz,et al.  Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. , 2004, Experimental neurology.

[41]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[42]  T. Südhof,et al.  Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2003, Neuroscience.

[43]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[44]  D. Dickson,et al.  Colocalization of Tau and Alpha‐Synuclein Epitopes in Lewy Bodies , 2003, Journal of neuropathology and experimental neurology.

[45]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[46]  J. Kuret,et al.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. , 2000, Journal of cell science.

[47]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[49]  T. Südhof,et al.  Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. , 2003, Neuroscience.

[50]  G. Johnson,et al.  Tau phosphorylation in neuronal cell function and dysfunction , 2004, Journal of Cell Science.

[51]  M. Barrachina,et al.  MPP+ increases α-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells , 2002, Brain Research.

[52]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W Slikker,et al.  Selective alterations of gene expression in mice induced by MPTP , 2005, Synapse.

[54]  W. Langston,et al.  α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates , 2005, Neurobiology of Disease.

[55]  R. Dobrowsky,et al.  Tau neurofibrillary pathology and microtubule stability , 2002, Journal of Molecular Neuroscience.

[56]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Sidhu,et al.  Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .

[58]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[59]  W. Blackstock,et al.  New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament‐Tau) from Alzheimer's Disease Brain Using Nanoelectrospray Mass Spectrometry , 1998, Journal of neurochemistry.

[60]  J. Payton,et al.  Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. , 2001, Brain research. Molecular brain research.

[61]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[62]  Kazuko Aoto,et al.  Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies , 1999, Brain Research.

[63]  J. Goudreau,et al.  Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. , 2004, Neurotoxicology.

[64]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[65]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[66]  E. Mandelkow,et al.  Structure of tau protein and assembly into paired helical filaments. , 2000, Biochimica et biophysica acta.

[67]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[68]  S. Lindley,et al.  Dopaminergic and beta-adrenergic receptor control of alpha-melanocyte-stimulating hormone secretion during stress. , 1990, Neuroendocrinology.

[69]  L. Benussi,et al.  Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. , 2005, Experimental cell research.

[70]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[71]  M. Barrachina,et al.  MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. , 2002, Brain research.

[72]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[73]  I. Grundke‐Iqbal,et al.  Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations* , 2004, Journal of Biological Chemistry.

[74]  J. M. Lee,et al.  Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein , 2005, Experimental Neurology.